共 39 条
- [21] Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 TrialJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07): : 917 - 923Callens, CelineVaur, DominiqueSoubeyran, IsabelleRouleau, EtienneJust, Pierre-AlexandreGuillerm, ErellGolmard, LisaGoardon, NicolasSevenet, NicolasCabaret, OdileHarter, PhilippGonzalez-Martin, AntonioFujiwara, KeiichiCecere, Sabrina ChiaraColombo, NicolettaMarth, ChristianVergote, IgnaceMaenpaa, JohannaPujade-Lauraine, EricRay-Coquard, Isabelle
- [22] Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Pautier, PatriciaHarter, PhilippPisano, CarmelaCropet, ClairePolo, Susana HernandoBerger, ReginaMatsumoto, TakashiVergote, IgnaceColombo, NicolettaNoettrup, Trine JakobiGarnier, GeorgesHillemanns, PeterZamagni, ClaudioMartin, Antonio GonzalezLefeuvre-Plesse, ClaudiaDenschlag, DominikLortholary, AlainSehouli, JalidSelle, FredericRay-Coquard, Isabelle Laure
- [23] Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Kurtz, Jean EmmanuelAnota, AmelieCropet, ClairePriou, FrankHarter, PhilippPignata, SandroPalacio, IsabelPetru, EdgarKobayashi, HiroakiVuylsteke, PeterParma, GabriellaMaenpaa, JohannaRaymond, EricBuderath, PaulLorusso, DomenicaHerrero, AnaRaban, NadiaPujade-Lauraine, EricJoly, FlorenceRay-Coquard, Isabelle Laure
- [24] Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysisANNALS OF ONCOLOGY, 2023, 34 (02) : 152 - 162Labidi-Galy, S. I.Rodrigues, M.Sandoval, J. L.Kurtz, J. E.Heitz, F.Mosconi, A. M.Romero, I.Denison, U.Nagao, S.Vergote, I.Parma, G.Nottrup, T. J.Rouleau, E.Garnier, G.El-Balat, A.Zamagni, C.Martin-Lorente, C.Pujade-Lauraine, E.Fievet, A.Ray-Coquard, I. L.
- [25] 5-Year Overall Survival (OS) of combined Maintenance Therapy of Olaparib (Ola) and Bevacizumab (Bev) as a Function of clinical Risk Profile in Patients with newly diagnosed advanced Ovarian Cancer - a post hoc Analysis of the Phase III AGO-OVAR20/PAOLA-1/ENGOT-ov25 TrialGEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 757 - 758Trillsch, F.Sehouli, J.Canzler, U.Heitz, F.Marme, F.de Gregorio, N.Buderath, P.El-Balat, A.Fasching, P.Schmalfeldt, B.Runnebaum, IBelau, A.Gropp-Meier, M.Lueck, H. J.Schnelzer, A.Hanker, L. C.Bauerschlag, D.Hillemanns, P.Denschlag, D.Marth, C.Coquard, Ray, IHarter, P.
- [26] RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinomaGYNECOLOGIC ONCOLOGY, 2021, 162 : S71 - S71Hietanen, SakariPautier, PatriciaHarter, PhilippCropet, ClaireCinieri, SaverioCaballero, CristinaMarth, ChristianFujiwara, HiroyukiVergote, IgnaceColombo, NicolettaLotz, Jean-PierreGropp-Meier, MartinaMosconi, Anna MariaManso, LuisLefeuvre-Plesse, ClaudiaLuck, Hans-JoachimLortholary, AlainSchnelzer, AndreasDubot, CoralineRay-Coquard, Isabelle
- [27] Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancerEUROPEAN JOURNAL OF CANCER, 2021, 157 : 415 - 423Vergote, IgnaceRay-Coquard, IsabelleAnderson, Daniel M.Cantuaria, GuilhermeColombo, NicolettaGarnier-Tixidre, ClaireGilbert, LucyHarter, PhilippHettle, RobertLorusso, DomenicaMaenpaa, JohannaMarth, ChristianMatsumoto, KojiOuwens, MarioPoveda, AndresRaspagliesi, FrancescoRhodes, KirstyPerez, Maria J. RubioShapira-Frommer, RonnieShikama, AyumiSikorska, MagdalenaMoore, KathleenDiSilvestro, Paul
- [28] Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutationGYNECOLOGIC ONCOLOGY, 2020, 159 : 19 - 20Vergote, I. B.Moore, K. N.Hettle, R.Rhodes, K.Ouwens, M.Ray-Coquard, I.
- [29] PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Ray-Coquard, IsabelleSelle, FredericHarter, PhilippCropet, ClaireMarth, ChristianVergote, IgnaceFujiwara, KeiichiGonzalez-Martin, AntonioPignata, SandroColombo, NicolettaMaenpaa, Johanna UnelmaPujade-Lauraine, Eric
- [30] PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Ray-Coquard, Isabelle LaureHarter, PhilippMartin, Antonio GonzalezCropet, ClairePignata, SandroFujiwara, KeiichiMarth, ChristianVergote, IgnaceMirza, Mansoor RazaColombo, NicolettaRosenberg, PerMaenpaa, Johanna Unelmalauraine, Eric PujaDe